Medicare Drug Spending
Medicare Part D and Part B spent $349.5B on drugs in 2024 before manufacturer rebates, up 7% from 2023. Mounjaro grew the most, from $2.36B to $6.34B.
- Spending, 2024: $349.5B
- 2023: $326.6B
- Drugs with spending: 4,424
Largest, 2024
Gross spending by brand, Part D and Part B.
- Eliquis (Part D)$20.8B
- Ozempic (Part D)$13.0B
- Jardiance (Part D)$11.4B
- Mounjaro (Part D)$6.34B
- Xarelto (Part D)$6.23B
- Keytruda (Part B)$5.99B
- Trulicity (Part D)$5.45B
- Trelegy Ellipta (Part D)$5.29B
- Farxiga (Part D)$5.29B
- Humira(Cf) Pen (Part D)$4.33B
- Revlimid (Part D)$4.18B
- Entresto (Part D)$4.02B
- Januvia (Part D)$3.81B
- Biktarvy (Part D)$3.46B
- Xtandi (Part D)$3.40B
Biggest Increases, 2023 to 2024
Dollar growth among drugs Medicare already paid for the year before. Part B skin substitutes are billed per square centimeter.
- Mounjaro (Part D): $2.36B to $6.34B+$3.98B
- Ozempic (Part D): $9.19B to $13.0B+$3.78B
- Jardiance (Part D): $8.84B to $11.4B+$2.60B
- Eliquis (Part D): $18.3B to $20.8B+$2.50B
- Vyndamax (Part D): $1.35B to $2.83B+$1.48B
- Complete ft, per square centimeter (Part B): $6.2M to $1.17B+$1.16B
- Membrane graft or membrane wrap, per square centimeter (Part B): $339M to $1.44B+$1.10B
- Lenalidomide (Part D): $1.68B to $2.64B+$960M
- Farxiga (Part D): $4.34B to $5.29B+$948M
- Brukinsa (Part D): $801M to $1.72B+$923M
- Trelegy Ellipta (Part D): $4.46B to $5.29B+$839M
- Xtandi (Part D): $2.60B to $3.40B+$799M
- Restorigin, per square centimeter (Part B): $2.4M to $732M+$729M
- Dupixent Pen (Part D): $1.08B to $1.80B+$723M
- Vabysmo (Part B): $1.30B to $1.92B+$621M
The 1,000 largest of 4,424 drugs, by 2024 spending
| Drug | Part | 2024 | 2023 | Change | Patients |
|---|---|---|---|---|---|
| EliquisApixaban | Part D | $20.8B | $18.3B | +14% | 4,424,796 |
| OzempicSemaglutide | Part D | $13.0B | $9.19B | +41% | 1,952,637 |
| JardianceEmpagliflozin | Part D | $11.4B | $8.84B | +29% | 2,543,331 |
| MounjaroTirzepatide | Part D | $6.34B | $2.36B | +168% | 894,581 |
| XareltoRivaroxaban | Part D | $6.23B | $6.31B | -1% | 1,321,019 |
| KeytrudaPembrolizumab | Part B | $5.99B | $5.43B | +10% | 75,361 |
| TrulicityDulaglutide | Part D | $5.45B | $7.36B | -26% | 788,716 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | Part D | $5.29B | $4.46B | +19% | 1,268,914 |
| FarxigaDapagliflozin Propanediol | Part D | $5.29B | $4.34B | +22% | 1,269,216 |
| Humira(Cf) PenAdalimumab | Part D | $4.33B | $4.42B | -2% | 63,768 |
| RevlimidLenalidomide | Part D | $4.18B | $3.86B | +8% | 38,868 |
| EntrestoSacubitril/Valsartan | Part D | $4.02B | $3.43B | +17% | 795,291 |
| JanuviaSitagliptin Phosphate | Part D | $3.81B | $4.09B | -7% | 828,288 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | Part D | $3.46B | $3.15B | +10% | 92,246 |
| XtandiEnzalutamide | Part D | $3.40B | $2.60B | +31% | 35,367 |
| StelaraUstekinumab | Part D | $3.38B | $2.99B | +13% | 24,754 |
| VyndamaxTafamidis | Part D | $2.83B | $1.35B | +110% | 13,925 |
| LenalidomideLenalidomide | Part D | $2.64B | $1.68B | +57% | 30,354 |
| Darzalex FasproDaratumumab-Hyaluronidase-Fihj | Part B | $2.53B | $2.08B | +22% | 26,517 |
| ProliaDenosumab | Part B | $2.43B | $2.19B | +11% | 700,724 |
| EyleaAflibercept | Part B | $2.37B | $3.15B | -25% | 293,280 |
| Enbrel SureclickEtanercept | Part D | $2.34B | $2.05B | +14% | 38,591 |
| MyrbetriqMirabegron | Part D | $2.30B | $2.51B | -8% | 762,957 |
| ImbruvicaIbrutinib | Part D | $2.27B | $2.37B | -4% | 15,351 |
| PomalystPomalidomide | Part D | $2.15B | $1.71B | +26% | 14,325 |
| OfevNintedanib Esylate | Part D | $2.09B | $1.84B | +14% | 23,929 |
| JakafiRuxolitinib Phosphate | Part D | $2.08B | $1.94B | +7% | 15,713 |
| IbrancePalbociclib | Part D | $2.04B | $2.02B | +1% | 15,923 |
| LinzessLinaclotide | Part D | $1.98B | $1.83B | +9% | 632,063 |
| IngrezzaValbenazine Tosylate | Part D | $1.96B | $1.71B | +15% | 32,171 |
| OpdivoNivolumab | Part B | $1.93B | $1.91B | +1% | 26,951 |
| VabysmoFaricimab-Svoa | Part B | $1.92B | $1.30B | +48% | 172,503 |
| RybelsusSemaglutide | Part D | $1.89B | $1.67B | +13% | 309,993 |
| Invega SustennaPaliperidone Palmitate | Part D | $1.88B | $1.82B | +3% | 72,112 |
| Dupixent PenDupilumab | Part D | $1.80B | $1.08B | +67% | 65,541 |
| Skyrizi PenRisankizumab-Rzaa | Part D | $1.78B | $1.19B | +50% | 27,003 |
| BrukinsaZanubrutinib | Part D | $1.72B | $801M | +115% | 18,031 |
| Repatha SureclickEvolocumab | Part D | $1.71B | $1.09B | +57% | 382,461 |
| CalquenceAcalabrutinib Maleate | Part D | $1.70B | $1.29B | +32% | 15,056 |
| TagrissoOsimertinib Mesylate | Part D | $1.63B | $1.23B | +32% | 12,370 |
| CreonLipase/Protease/Amylase | Part D | $1.49B | $1.47B | +2% | 185,261 |
| Membrane graft or membrane wrap, per square centimeter | Part B | $1.44B | $339M | +325% | 10,459 |
| ErleadaApalutamide | Part D | $1.39B | $1.06B | +31% | 13,253 |
| RinvoqUpadacitinib | Part D | $1.39B | $976M | +42% | 29,062 |
| Breo ElliptaFluticasone/Vilanterol | Part D | $1.36B | $1.37B | -1% | 596,052 |
| RestasisCyclosporine | Part D | $1.29B | $1.50B | -14% | 472,657 |
| OpsumitMacitentan | Part D | $1.23B | $1.02B | +21% | 10,962 |
| CabometyxCabozantinib S-Malate | Part D | $1.22B | $1.11B | +10% | 9,182 |
| Complete ft, per square centimeter | Part B | $1.17B | $6.2M | +18769% | 5,091 |
| XifaxanRifaximin | Part D | $1.16B | $1.09B | +6% | 104,805 |
| VraylarCariprazine HCl | Part D | $1.14B | $936M | +21% | 117,573 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | Part D | $1.13B | $796M | +42% | 367,055 |
| TradjentaLinagliptin | Part D | $1.13B | $1.29B | -13% | 274,523 |
| AustedoDeutetrabenazine | Part D | $1.07B | $1.12B | -5% | 18,418 |
| VerzenioAbemaciclib | Part D | $1.06B | $757M | +40% | 11,239 |
| OtezlaApremilast | Part D | $1.05B | $877M | +19% | 31,045 |
| NubeqaDarolutamide | Part D | $998M | $576M | +73% | 11,577 |
| Tresiba Flextouch U-200Insulin Degludec | Part D | $974M | $1.05B | -7% | 217,424 |
| GemtesaVibegron | Part D | $945M | $508M | +86% | 320,270 |
| VenclextaVenetoclax | Part D | $942M | $815M | +16% | 21,868 |
| OrenciaAbatacept | Part B | $930M | $903M | +3% | 33,154 |
| UptraviSelexipag | Part D | $909M | $758M | +20% | 4,320 |
| Spiriva RespimatTiotropium Bromide | Part D | $877M | $924M | -5% | 327,575 |
| LenvimaLenvatinib Mesylate | Part D | $876M | $779M | +12% | 8,450 |
| RexultiBrexpiprazole | Part D | $861M | $630M | +37% | 94,695 |
| ImfinziDurvalumab | Part B | $843M | $739M | +14% | 14,791 |
| Tresiba Flextouch U-100Insulin Degludec | Part D | $826M | $727M | +14% | 339,158 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | Part D | $819M | $873M | -6% | 291,195 |
| Cosentyx Sensoready (2 Pens)Secukinumab | Part D | $818M | $853M | -4% | 14,195 |
| ShingrixVaricella-Zoster Ge/As01b/PF | Part D | $776M | $1.21B | -36% | 2,933,003 |
| KisqaliRibociclib Succinate | Part D | $775M | $371M | +109% | 8,782 |
| ArexvyRsvpref3 Antigen/As01e/PF | Part D | $774M | $1.39B | -44% | 2,820,344 |
| ProliaDenosumab | Part D | $772M | $673M | +15% | 284,965 |
| EntyvioVedolizumab | Part B | $769M | $728M | +6% | 19,661 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | Part B | $765M | $740M | +3% | 26,102 |
| EpclusaSofosbuvir/Velpatasvir | Part D | $758M | $877M | -14% | 12,242 |
| Atorvastatin CalciumAtorvastatin Calcium | Part D | $756M | $1000M | -24% | 17,830,813 |
| ReblozylLuspatercept-Aamt | Part B | $755M | $451M | +67% | 6,466 |
| Restorigin, per square centimeter | Part B | $732M | $2.4M | +30150% | 5,256 |
| Tyvaso DpiTreprostinil | Part D | $729M | $437M | +67% | 4,385 |
| TrikaftaElexacaftor/Tezacaftor/IVacaft | Part D | $725M | $675M | +7% | 2,732 |
| VascepaIcosapent Ethyl | Part D | $724M | $764M | -5% | 301,070 |
| OxervateCenegermin-Bkbj | Part D | $715M | $493M | +45% | 4,781 |
| JanumetSitagliptin Phos/Metformin HCl | Part D | $709M | $799M | -11% | 159,321 |
| Lantus SolostarInsulin Glargine,Hum.Rec.Anlog | Part D | $699M | $3.16B | -78% | 1,415,422 |
| Humira PenAdalimumab | Part D | $697M | $835M | -16% | 11,719 |
| ComirnatyCovid Vac (12up)(Raxt)/PF | Part B | $696M | $440M | +58% | 4,283,296 |
| AdempasRiociguat | Part D | $694M | $598M | +16% | 5,553 |
| Abiraterone AcetateAbiraterone Acetate | Part D | $693M | $877M | -21% | 55,274 |
| Dupixent SyringeDupilumab | Part D | $687M | $633M | +8% | 22,833 |
| BrilintaTicagrelor | Part D | $685M | $692M | -1% | 242,931 |
| TecentriqAtezolizumab | Part B | $678M | $755M | -10% | 10,191 |
| PromactaEltrombopag Olamine | Part D | $672M | $558M | +21% | 6,666 |
| OcrevusOcrelizumab | Part B | $669M | $697M | -4% | 11,764 |
| Eylea HdAflibercept | Part B | $666M | — | New | 66,767 |
| Basaglar Kwikpen U-100Insulin Glargine,Hum.Rec.Anlog | Part D | $665M | $648M | +3% | 422,745 |
| NuplazidPimavanserin Tartrate | Part D | $658M | $596M | +10% | 17,122 |
| LumiganBimatoprost | Part D | $647M | $697M | -7% | 336,870 |
| Abilify MaintenaAripiprazole | Part D | $644M | $637M | +1% | 29,911 |
| PadcevEnfortumab Vedotin-Ejfv | Part B | $641M | $312M | +106% | 5,839 |
| Evenity (2 Syringes)Romosozumab-Aqqg | Part B | $639M | $451M | +42% | 52,146 |
| Helicoll, per square centimeter | Part B | $637M | $51.3M | +1143% | 2,421 |
| EnbrelEtanercept | Part D | $633M | $627M | +1% | 10,542 |
| TivicayDolutegravir Sodium | Part D | $629M | $657M | -4% | 29,205 |
| Nurtec ODTRimegepant Sulfate | Part D | $625M | $478M | +31% | 105,323 |
| TremfyaGuselkumab | Part D | $619M | $531M | +16% | 10,848 |
| UltomirisRavulizumab-Cwvz | Part B | $609M | $472M | +29% | 1,844 |
| SymbicortBudesonide/Formoterol Fumarate | Part D | $598M | $2.00B | -70% | 588,018 |
| ZenpepLipase/Protease/Amylase | Part D | $597M | $443M | +35% | 58,375 |
| Austedo XRDeutetrabenazine | Part D | $597M | $91.0M | +556% | 11,299 |
| SpikevaxCovid Vac (12up)(Andu)/PF | Part B | $597M | $509M | +17% | 3,479,068 |
| LynparzaOlaparib | Part D | $594M | $487M | +22% | 7,016 |
| Xeljanz XRTofacitinib Citrate | Part D | $590M | $586M | +1% | 12,581 |
| Kesimpta PenOfatumumab | Part D | $583M | $413M | +41% | 7,188 |
| EnhertuFam-Trastuzumab Deruxtecn-Nxki | Part B | $581M | $465M | +25% | 8,410 |
| Gammagard LiquidImmun Glob G(IgG)/Gly/IgA Ov50 | Part D | $581M | $543M | +7% | 4,679 |
| Orencia ClickjectAbatacept | Part D | $570M | $451M | +26% | 13,548 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | Part D | $566M | $632M | -10% | 16,151 |
| Taltz AutoinjectorIxekizumab | Part D | $564M | $475M | +19% | 10,132 |
| Toujeo Max SolostarInsulin Glargine,Hum.Rec.Anlog | Part D | $561M | $489M | +15% | 134,394 |
| Fluzone High-DoseFlu Vacc TS(65yr Up)/PF | Part B | $560M | $428M | +31% | 6,956,496 |
| Albuterol Sulfate HFAAlbuterol Sulfate | Part D | $553M | $584M | -5% | 6,698,365 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | Part D | $552M | $626M | -12% | 14,573 |
| Toujeo SolostarInsulin Glargine,Hum.Rec.Anlog | Part D | $550M | $542M | +1% | 189,494 |
| Invega TrinzaPaliperidone Palmitate | Part D | $550M | $530M | +4% | 19,150 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | Part B | $545M | $463M | +18% | 15,316 |
| DescovyEmtricitabine/Tenofov Alafenam | Part D | $545M | $590M | -8% | 30,179 |
| GabapentinGabapentin | Part D | $544M | $656M | -17% | 7,960,881 |
| DovatoDolutegravir Sodium/Lamivudine | Part D | $541M | $433M | +25% | 19,337 |
| Prevnar 20Pneumoc 20-Val Conj-Dip Crm/PF | Part B | $525M | $574M | -9% | 1,840,975 |
| Gamunex-CImmune Globul G/Gly/IgA Avg 46 | Part D | $521M | $483M | +8% | 5,150 |
| SprycelDasatinib | Part D | $518M | $510M | +2% | 5,393 |
| YervoyIpilimumab | Part B | $509M | $459M | +11% | 8,483 |
| XiidraLifitegrast | Part D | $505M | $473M | +7% | 166,361 |
| PrivigenImmun Glob G(IgG)/Pro/IgA 0-50 | Part D | $494M | $382M | +29% | 3,912 |
| Spiriva HandihalerTiotropium Bromide | Part D | $486M | $783M | -38% | 157,377 |
| OrgovyxRelugolix | Part D | $484M | $277M | +75% | 28,521 |
| BotoxOnabotulinumtoxina | Part B | $479M | $445M | +8% | 165,103 |
| AbrysvoRsv Vacc, Pref A And Pref B/PF | Part D | $468M | $698M | -33% | 1,621,026 |
| Levothyroxine SodiumLevothyroxine Sodium | Part D | $464M | $654M | -29% | 9,003,268 |
| Actemra (J3262)Tocilizumab | Part B | $463M | $416M | +11% | 19,715 |
| Metoprolol SuccinateMetoprolol Succinate | Part D | $456M | $588M | -22% | 7,767,909 |
| Sandostatin Lar DepotOctreotide Acetate,mi-Spheres | Part B | $450M | $447M | +1% | 8,853 |
| Stiolto RespimatTiotropium Br/Olodaterol HCl | Part D | $449M | $432M | +4% | 167,334 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | Part D | $448M | $469M | -4% | 10,616 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | Part B | $440M | $377M | +17% | 13,330 |
| InlytaAxitinib | Part D | $439M | $467M | -6% | 4,465 |
| VelphoroSucroferric Oxyhydroxide | Part D | $438M | $466M | -6% | 38,351 |
| RituxanRituximab | Part B | $437M | $484M | -10% | 22,261 |
| Rosuvastatin CalciumRosuvastatin Calcium | Part D | $437M | $604M | -28% | 8,211,366 |
| UbrelvyUbrogepant | Part D | $430M | $315M | +37% | 83,437 |
| TasignaNilotinib HCl | Part D | $427M | $395M | +8% | 3,054 |
| VyvgartEfgartigimod Alfa-Fcab | Part B | $417M | $297M | +40% | 1,803 |
| JulucaDolutegravir/Rilpivirine | Part D | $415M | $392M | +6% | 12,112 |
| XolairOmalizumab | Part B | $415M | $420M | -1% | 17,605 |
| MultaqDronedarone HCl | Part D | $415M | $409M | +1% | 72,761 |
| IlumyaTildrakizumab-Asmn | Part B | $413M | $344M | +20% | 9,049 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | Part D | $409M | $414M | -1% | 779,878 |
| SyfovrePegcetacoplan/PF | Part B | $404M | $76.7M | +427% | 29,338 |
| Humira(Cf)Adalimumab | Part D | $401M | $446M | -10% | 6,661 |
| CimziaCertolizumab Pegol | Part B | $398M | $401M | -1% | 25,557 |
| KyprolisCarfilzomib | Part B | $397M | $401M | -1% | 5,806 |
| KerendiaFinerenone | Part D | $396M | $270M | +47% | 88,208 |
| OctagamImmun Globg(IgG)/Malt/IgA Ov50 | Part D | $393M | $301M | +31% | 3,206 |
| TrintellixVortioxetine Hydrobromide | Part D | $392M | $390M | +1% | 100,706 |
| Skyrizi On-BodyRisankizumab-Rzaa | Part D | $391M | $125M | +212% | 4,897 |
| Combivent RespimatIpratropium/Albuterol Sulfate | Part D | $388M | $456M | -15% | 154,264 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | Part D | $387M | $423M | -9% | 5,266,914 |
| Cosentyx Unoready PenSecukinumab | Part D | $378M | $19.2M | +1866% | 6,469 |
| Incruse ElliptaUmeclidinium Bromide | Part D | $376M | $456M | -18% | 185,597 |
| Radicava OrsEdaravone | Part D | $376M | $294M | +28% | 3,530 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | Part D | $375M | $384M | -2% | 10,329 |
| OmeprazoleOmeprazole | Part D | $367M | $422M | -13% | 7,509,766 |
| InfliximabInfliximab | Part B | $367M | $390M | -6% | 36,967 |
| NPlateRomiplostim | Part B | $362M | $323M | +12% | 6,523 |
| OpdualagNivolumab-Relatlimab-Rmbw | Part B | $362M | $254M | +43% | 2,535 |
| ActharCorticotropin | Part D | $360M | $378M | -5% | 836 |
| Janumet XRSitagliptin Phos/Metformin HCl | Part D | $358M | $392M | -9% | 85,930 |
| GattexTeduglutide | Part D | $358M | $330M | +8% | 962 |
| Losartan PotassiumLosartan Potassium | Part D | $355M | $487M | -27% | 8,911,001 |
| Lanreotide Acetate (J1930)Lanreotide Acetate | Part B | $354M | $368M | -4% | 7,615 |
| LibtayoCemiplimab-Rwlc | Part B | $348M | $270M | +29% | 5,482 |
| SynthroidLevothyroxine Sodium | Part D | $348M | $355M | -2% | 1,125,443 |
| StrensiqAsfotase Alfa | Part D | $346M | $259M | +34% | 290 |
| Diclofenac SodiumDiclofenac Sodium | Part D | $342M | $396M | -14% | 2,566,155 |
| KorlymMifepristone | Part D | $342M | $229M | +49% | 1,700 |
| OjjaaraMomelotinib Dihydrochloride | Part D | $342M | $27.0M | +1165% | 2,316 |
| Praluent PenAlirocumab | Part D | $341M | $476M | -28% | 92,483 |
| OxycontinOxycodone HCl | Part D | $338M | $391M | -14% | 61,465 |
| SolirisEculizumab | Part B | $337M | $416M | -19% | 956 |
| Humalog Kwikpen U-100Insulin Lispro | Part D | $334M | $1.21B | -72% | 447,128 |
| Simponi AriaGolimumab | Part B | $330M | $365M | -10% | 33,452 |
| Pantoprazole SodiumPantoprazole Sodium | Part D | $321M | $384M | -16% | 6,692,955 |
| Synjardy XREmpagliflozin/Metformin HCl | Part D | $321M | $278M | +15% | 70,976 |
| Advair HFAFluticasone Propion/Salmeterol | Part D | $321M | $398M | -20% | 200,081 |
| Novolog FlexpenInsulin Aspart | Part D | $319M | $1.88B | -83% | 479,549 |
| Dual layer impax membrane, per square centimeter | Part B | $318M | $1.41B | -77% | 1,678 |
| NucalaMepolizumab | Part D | $318M | $261M | +22% | 9,062 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | Part B | $318M | $294M | +8% | 5,165 |
| Amlodipine BesylateAmlodipine Besylate | Part D | $316M | $407M | -22% | 12,195,951 |
| SkyriziRisankizumab-Rzaa | Part D | $316M | $289M | +9% | 5,557 |
| XolairOmalizumab | Part D | $313M | $254M | +23% | 11,011 |
| Membrane wrap-hydro, per square centimeter | Part B | $310M | — | New | 1,807 |
| Duloxetine HClDuloxetine HCl | Part D | $309M | $399M | -23% | 2,658,016 |
| Tamsulosin HClTamsulosin HCl | Part D | $308M | $396M | -22% | 5,498,981 |
| Aimovig AutoinjectorErenumab-Aooe | Part D | $306M | $327M | -7% | 55,791 |
| CyclosporineCyclosporine | Part D | $305M | $256M | +19% | 277,946 |
| VyndaqelTafamidis Meglumine | Part D | $304M | $118M | +157% | 2,021 |
| FluadFlu Vacc TS(65up)/Mf59c/PF | Part B | $303M | $267K | +113287% | 3,768,112 |
| WegovySemaglutide | Part D | $301M | $200K | +150712% | 52,961 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | Part D | $300M | $303M | -1% | 59,472 |
| PerjetaPertuzumab | Part B | $297M | $309M | -4% | 5,766 |
| LeqvioInclisiran Sodium | Part B | $296M | $143M | +107% | 48,298 |
| GammaplexImmun Glob G(IgG)/Gly/IgA 0-50 | Part D | $295M | $265M | +11% | 1,829 |
| Potassium ChloridePotassium Chloride | Part D | $291M | $396M | -27% | 3,573,756 |
| CamzyosMavacamten | Part D | $291M | $105M | +177% | 4,490 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | Part D | $289M | $106M | +173% | 131,189 |
| KrystexxaPegloticase | Part B | $283M | $247M | +15% | 1,097 |
| Amnicore pro+, per square centimeter | Part B | $281M | — | New | 1,474 |
| Neostim tl, per square centimeter | Part B | $274M | — | New | 1,202 |
| XeljanzTofacitinib Citrate | Part D | $274M | $280M | -2% | 6,688 |
| NinlaroIxazomib Citrate | Part D | $273M | $312M | -13% | 2,983 |
| TrodelvySacituzumab Govitecan-Hziy | Part B | $272M | $231M | +18% | 3,300 |
| InvokanaCanagliflozin | Part D | $272M | $357M | -24% | 55,993 |
| RytaryCarbidopa/Levodopa | Part D | $272M | $267M | +2% | 34,890 |
| GammakedImmune Globul G/Gly/IgA Avg 46 | Part D | $270M | $220M | +23% | 1,846 |
| AristadaAripiprazole Lauroxil | Part D | $269M | $273M | -1% | 13,102 |
| CaplytaLumateperone Tosylate | Part D | $268M | $195M | +38% | 27,010 |
| NucalaMepolizumab | Part B | $267M | $255M | +5% | 8,671 |
| ForteoTeriparatide | Part D | $266M | $425M | -37% | 11,433 |
| TibsovoIVosidenib | Part D | $265M | $184M | +44% | 1,503 |
| Cimzia (2 Pack)Certolizumab PEGol | Part D | $264M | $257M | +3% | 5,554 |
| AbraxanePaclitaxel Protein-Bound | Part B | $263M | $284M | -7% | 13,324 |
| QuliptaAtogepant | Part D | $260M | $138M | +89% | 45,046 |
| OrserduElacestrant HCl | Part D | $259M | $128M | +103% | 2,633 |
| Emgality PenGalcanezumab-Gnlm | Part D | $258M | $229M | +13% | 51,883 |
| TymlosAbaloparatide | Part D | $258M | $198M | +30% | 16,530 |
| CopaxoneGlatiramer Acetate | Part D | $257M | $369M | -30% | 4,785 |
| Enbrel MiniEtanercept | Part D | $256M | $269M | -5% | 4,128 |
| PrezcobixDarunavir/Cobicistat | Part D | $255M | $272M | -6% | 11,230 |
| PremarinEstrogens, Conjugated | Part D | $255M | $279M | -9% | 231,894 |
| LisinoprilLisinopril | Part D | $253M | $332M | -24% | 8,758,393 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,Auto,Bt,G6/7 | Part D | $252M | $160M | +57% | 44,543 |
| Cosentyx Sensoready PenSecukinumab | Part D | $248M | $205M | +21% | 4,582 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | Part D | $248M | $140M | +77% | 399,801 |
| Amnio quad-core, per square centimeter | Part B | $248M | — | New | 1,400 |
| AlecensaAlectinib HCl | Part D | $247M | $186M | +33% | 1,906 |
| TepezzaTeprotumumab-Trbw | Part B | $246M | $274M | -10% | 962 |
| AripiprazoleAripiprazole | Part D | $245M | $373M | -34% | 647,122 |
| Oxycodone-AcetaminophenOxycodone HCl/Acetaminophen | Part D | $243M | $263M | -7% | 2,149,560 |
| RezurockBelumosudil Mesylate | Part D | $243M | $146M | +66% | 1,371 |
| FasenraBenralizumab | Part B | $241M | $232M | +4% | 9,899 |
| VyvgartEfgartigimod Alfa-Fcab | Part D | $241M | $200M | +20% | 947 |
| Humulin R U-500 KwikpenInsulin Regular, Human | Part D | $240M | $264M | -9% | 26,329 |
| LokelmaSodium Zirconium Cyclosilicate | Part D | $239M | $205M | +17% | 116,877 |
| Actemra ActpenTocilizumab | Part D | $236M | $185M | +28% | 9,054 |
| BosulifBosutinib | Part D | $235M | $199M | +18% | 1,981 |
| Orion, per square centimeter | Part B | $235M | $82.8M | +184% | 984 |
| UltomirisRavulizumab-Cwvz | Part D | $233M | $160M | +46% | 701 |
| Complete aa, per square centimeter | Part B | $233M | — | New | 548 |
| Xtampza EROxycodone Myristate | Part D | $233M | $250M | -7% | 50,981 |
| Amnio-maxx or amnio-maxx lite, per square centimeter | Part B | $232M | $376K | +61497% | 1,858 |
| Fasenra PenBenralizumab | Part D | $232M | $173M | +34% | 8,489 |
| Orenitram ERTreprostinil Diolamine | Part D | $230M | $183M | +26% | 1,268 |
| HemlibraEmicizumab-Kxwh | Part B | $230M | $233M | -1% | 438 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | Part B | $230M | $199M | +15% | 8,749 |
| AmvuttraVutrisiran Sodium | Part B | $229M | $167M | +37% | 603 |
| Prolastin CAlpha-1-Proteinase Inhibitor | Part D | $229M | $246M | -7% | 2,056 |
| Humalog Kwikpen U-200Insulin Lispro | Part D | $228M | $224M | +2% | 45,830 |
| LonsurfTrifluridine/Tipiracil HCl | Part D | $226M | $176M | +28% | 3,946 |
| ZejulaNiraparib Tosylate | Part D | $224M | $162M | +39% | 2,016 |
| TakhzyroLanadelumab-Flyo | Part D | $223M | $194M | +15% | 512 |
| Dexlansoprazole DrDexlansoprazole | Part D | $220M | $315M | -30% | 175,211 |
| BriviactBrivaracetam | Part D | $220M | $184M | +19% | 15,497 |
| TezspireTezepelumab-Ekko | Part B | $218M | $138M | +58% | 7,618 |
| EstradiolEstradiol | Part D | $218M | $239M | -9% | 1,611,030 |
| CimerliRanibizumab-Eqrn | Part B | $217M | $122M | +77% | 38,028 |
| BenlystaBelimumab | Part D | $217M | $187M | +16% | 5,831 |
| Bydureon BciseExenatide Microspheres | Part D | $215M | $284M | -24% | 38,059 |
| EligardLeuprolide Acetate | Part B | $213M | $215M | -1% | 141,546 |
| ElahereMirvetuximab Soravtansine-Gynx | Part B | $213M | $88.3M | +141% | 1,757 |
| TeriparatideTeriparatide | Part D | $213M | $89.1M | +139% | 15,831 |
| KrystexxaPEGloticase | Part D | $212M | $179M | +19% | 662 |
| CabenuvaCabotegravir/Rilpivirine | Part D | $212M | $166M | +28% | 6,592 |
| XywavSodium,Calcium,Mag,Pot Oxybate | Part D | $211M | $169M | +25% | 1,471 |
| HumiraAdalimumab | Part D | $209M | $258M | -19% | 3,912 |
| EzetimibeEzetimibe | Part D | $209M | $290M | -28% | 2,411,057 |
| EpidiolexCannabidiol (Cbd) | Part D | $207M | $197M | +5% | 4,517 |
| MekinistTrametinib Dimethyl Sulfoxide | Part D | $207M | $173M | +19% | 2,654 |
| WeliregBelzutifan | Part D | $205M | $59.8M | +243% | 1,896 |
| Derm-maxx, per square centimeter | Part B | $204M | $3.7M | +5422% | 1,150 |
| MesalamineMesalamine | Part D | $204M | $271M | -25% | 104,700 |
| Xigduo XRDapaglifloz Propaned/Metformin | Part D | $204M | $199M | +2% | 46,616 |
| Victoza 3-PakLiraglutide | Part D | $203M | $1.00B | -80% | 62,754 |
| DapagliflozinDapagliflozin Propanediol | Part D | $202M | — | New | 223,069 |
| PolivyPolatuzumab Vedotin-Piiq | Part B | $202M | $119M | +69% | 3,042 |
| JaypircaPirtobrutinib | Part D | $201M | $49.3M | +307% | 1,795 |
| TecvayliTeclistamab-Cqyv | Part B | $200M | $88.2M | +127% | 1,549 |
| Arnuity ElliptaFluticasone Furoate | Part D | $200M | $98.3M | +103% | 181,821 |
| Buprenorphine-NaloxoneBuprenorphine HCl/Naloxone HCl | Part D | $200M | $231M | -14% | 162,393 |
Gross Medicare spending by drug from CMS's yearly dashboards: Part D (pharmacy) and Part B (drugs given in clinics and hospital outpatient settings). Totals are before manufacturer rebates and discounts, so net spending is lower. Part D counts each brand's total across manufacturers. CMS publishes one year at a time. CMS Medicare Part D and Part B Spending by Drug